Thursday, February 3, 2011
UT Southwestern Medical Center psychiatry researchers are leading the Texas arm of a national network that conducts clinical trials aimed at finding effective treatments for drug addiction. More than 100 community treatment providers and academic medical centers throughout the country are funded in part through the National Institute on Drug Abuse’s Clinical Trials Network (CTN)…
A recent conference sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) in collaboration with the Heffter Research Institute, the Beckley Foundation and the Council on Spiritual Practices held from April 15th to 18th 2010, in San José, USA () united 90 presenters and 1100 participants with the goal of giving visibility to studies on the therapeutic potentials of psychedelics (psilocybin, MDMA, ibogaine, ayahuasca, etc.) in the treatment of often intractable ailments such as anxiety in terminal cancer patients, cluster headaches, obsessive–compulsive disorders, drug addiction, and post-traumatic stress disorders, as well as the role of these substances in human enhancement and well-being in general. MAPS was chartered in 1986, with the mission to develop cannabis and psychedelics into prescription medicines to treat illnesses, to build a network of clinics where these prescription medicines can be administered, and to provide public education on the harm and benefits of using psychedelics and cannabis.
Filed in Evidence Base, cannabis
|
Also tagged beckley, been-criticized, council, dangerous-drugs, development, focused-or-too, important, maps, over-the-years, permission, psychedelic, such-as-anxiety, the-psychedelic, therapeutic
|
Aim To investigate the association between alcohol use and adherence to highly active antiretroviral treatment (HAART) among human immunodeficiency virus (HIV)-infected patients in subSaharan Africa.Design and setting Cross-sectional survey conducted in eight adult HIV treatment centres from Benin, Côte d’Ivoire and Mali.Participants and measurements During a 4-week period, health workers administered the Alcohol Use Disorders Identification Test to HAART-treated patients and assessed treatment adherence using the AIDS Clinical Trials Group follow-up questionnaire.Findings A total of 2920 patients were enrolled with a median age of 38 years [interquartile range (IQR) 32[ndash]45 years] and a median duration on HAART of 3 years (IQR 1[ndash]4 years). Overall, 91.8% of patients were identified as adherent to HAART.
Filed in Evidence Base
|
Also tagged africa-adult, aids, alcohol, association, benin, between-alcohol, cross-sectional, highly-active, median-duration, the-association, using-the-aids
|
Sunday, February 28, 2010
Cannabis Science Inc. (NASD OTCBB: CBIS), a pharmaceutical cannabis company, is pleased to report to their shareholders that the choice of our initial cannabis-based pharmaceutical for FDA clinical trials has been made. The Company has reported several possible drugs for FDA clinical trials…
Filed in Uncategorized, cannabis
|
Also tagged cbis, choice, fda, initial, nasd, otcbb, our-initial, science, several-possible, shareholders, their-shareholders
|